Oslo, 22 July 2024: Reference is made to the stock exchange announcement by
Circio Holding ASA (the "Company") on 9 July 2024 regarding the final results of
the rights issue (the "Rights Issue").

The share capital increase relating to the Rights Issue and the share capital
increase relating to the settlement of commission to the pre-subscribers in the
Rights Issue are now registered with the Norwegian Register of Business
Enterprises. After this, the Company's new share capital is NOK 11,111,804.40
divided into 18,519,674 shares, each with a nominal value of NOK 0.60.

The new shares are expected to be tradable on or about 23 July 2024. The
subscribers in the Rights Issue were also allocated one warrant for every share
allocated to them and paid by them in the Rights Issue (the "Warrants"). The
Company will inform in a stock exchange announcement once the Warrants has been
registered with the Norwegian Register of Business Enterprises and delivered to
each investor in the Rights Issue.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio Holding ASA
Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines. Circio has established a unique circular
RNA (circRNA) platform for genetic medicine. The proprietary circVec technology
is based on a modular genetic cassette design for efficient biogenesis of
multifunctional circRNA from DNA and viral vectors, which can be deployed in
multiple disease settings. The circVec platform has demonstrated enhanced and
more durable protein expression than classic mRNA vector systems, and has the
potential to become the new gold-standard for DNA and virus-based therapeutics
in the future. The circRNA R&D activities are being conducted by the wholly
owned subsidiary Circio AB based at the Karolinska Institute in Stockholm,
Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.

This information is published in accordance with the requirements of the Oslo
Rule Book II and is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.